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Background:  Ticagrelor  is  an  orally  available,  direct  acting  and  reversible  P2Y12 receptor
antagonist  approved  for  treatment  of acute  coronary  syndrome.  The  objectives  of these
studies were  to (1)  evaluate  the  Ticagrelor  2-year  rat  carcinogenicity  bioassay  data;  (2)
investigate  potential  mode  of action  (MOA)  and  (3)  interpret  human  relevance.
Methods: The  following  studies  were  done (1)  rat two-year  carcinogenicity  study  in male
and female  rats,  (2)  in  vitro  and  in  vivo  genotoxicity  assays,  (3)  quantitative  whole  body
autoradiography  (QWBA;  male  and  female  rats), (4)  in vitro  pharmacological  proﬁling  for
more than  300  assays,  and  (5)  in  vivo ovariectomized  rat  assay.
Results: The  carcinogenicity  study  indicated  Ticagrelor  increased  uterine  tumor  incidence
while decreasing  mammary  and  pituitary  tumors/hyperplasia  incidences  in  only  high dose
female rats.  However,  this  altered  tumor  incidences  were  not  P2Y12 target  related  sinceUterine  tumor marketed  non-reversible  P2Y12 receptor  antagonists  were  not  associated  with  alter  tumor
incidences.  MOA  studies  determined  Ticagrelor  exposure  in the  anterior  pituitary  and  Tica-
grelor was  (1)  non-genotoxic,  (2) peripherally-restricted,  (3)  a dopamine  transport  (DAT)
inhibitor with an IC50 lower  than  systemic  free  exposure  in  the rat  carcinogenic  study and
more  than  a log  higher  than the  free  systemic  exposure  seen  in  clinical  trials and  (4)  an
inhibitor  of estradiol-induced  prolactin  secretion.Abbreviations: ADP, adenosine-5′-diphosphate; AUC, area under the curve; CHO, Chinese hamster ovary; Cmax, maximal concentration, DAT, dopamine
transport;  E2, estradiol; GLP, good laboratory practice; H&E, hematoxylin and eosin; IC50, inhibitory concentration ﬁfty percent; Ki , inhibition concentration;
LC-MS/MS,  liquid chromatography-mass spectrometric; LLOQ, lower limits of quantiﬁcation; MOA, mode of action; MTD, maximum tolerated dose; NH ,
Hill  coefﬁcient; QWBA, quantitative whole body autoradiography; TK, toxicokinetics.
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Similar  to Ticagrelor,  centrally  active  dopamine  agonists  induce  the same  altered  tumor
incidence  patterns  that according  to  literature  do not  translate  into  the clinical  set-
ting,  with  a MOA  involving  decreased  prolactin  secretion.  The  Ticagrelor  MOA  data
and  literature  suggest  that altered  dopamine  levels  in the  hypophyseal  part  of  the
hypothalamus–hypophyseal  axis  (by  Ticagrelor)  will  result  in  similar  altered  tumor  inci-
dences  in  rat  that  do not  translate  into  the  clinical  setting,  based  on  qualitative  species
differences.  In conclusion  Ticagrelor  increased  uterine  tumors  in  the rat  carcinogenesis
study  by  a MOA  consistent  with  reduced  dopamine  inhibition  of  prolactin,  which  is  not  a
patient  safety  risk.
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. Introduction
Ticagrelor (AZD6140; brand names BriliqueTM and
rilintaTM, AstraZeneca) is an orally available, direct act-
ng,  competitive and reversible P2Y12 receptor antagonist,
hich has therapeutic utility as an oral antiplatelet agent
or  treatment of acute coronary syndrome and poten-
ially other conditions [1]. The risk of ischemic events
s  high after acute coronary syndrome and so inhibition
f platelet aggregation is a major strategy for preven-
ing ischemia in these patients [51]. Platelet aggregation
s a complex process involving many factors, but a major
ediator of aggregation is the release of adenosine-5′-
iphosphate (ADP) from activated platelets leading to
ustained activation of the P2Y12 receptor [52,53]. The
2Y12 receptor antagonist activity was demonstrated by
icagrelor (100 mg  b.i.d.) inhibiting platelet aggregation
y greater than 90% at 4, 12 and 24 h, in humans
54].
The P2Y12 receptor is expressed by platelets, brain, vas-
ular  smooth muscle cells, dendritic cells and other blood
ells  [2,3] and is the molecular target of various antiplatelet
rugs such as Ticagrelor and the irreversible P2Y12 antag-
nists Clopidogrel and Prasugrel [4,5]. Expression in the
rain  is equally abundant in the amygdala, caudate nucleus,
orpus  callosum, hippocampus, substantia nigra and thal-
mus  which are consistent with microglial expression
attern [3]. P2Y12 mRNA transcripts were detected [6], but
eceptor  expression was not detected in the anterior pitu-
tary  cells [7].
Currently most compounds to which patients will be
xposed for more than 6 months duration must be evalu-
ted  for carcinogenicity potential during drug development
8].  The two-year rat carcinogenicity bioassay, as outlined
n  the International Conference on Harmonization guid-
nce  documents (ICH S1, S2, S3), is used in conjunction with
ther  assays to determine the carcinogenicity potential of
ompounds. Human patient safety risk (if any) is deter-
ined based on the human relevance framework [9–11].
his  framework leverages two concepts to determine a
tatement of conﬁdence regarding patient safety risk: (1)
s  the weight of evidence sufﬁcient to establish the mode
f  action (MOA) in animals and (2) is the MOA  plausible in
umans.  Therefore, determining the MOA  of a carcinoge-
icity ﬁnding is critical to accurately determine the human
elevance of any ﬁndings from the carcinogenicity bioas-
ays.  The human relevance framework helps classify the
uman  patient safety risk from high conﬁdence in theished  by  Elsevier  Ireland  Ltd. This  is an  open  access  article  under
-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
rodent  carcinogenicity data translating into patient safety
risk,  to the mechanism of action studies determining the
rat  carcinogenicity data has a MOA  not plausible in human
and  thereby no patient safety risk.
For example, central-acting dopamine agonists altered
tumor incidences in rats is an example of lack of conﬁdence
in  the MOA  translating into human (Fig. 1). This is because
altered brain dopamine levels inhibit pituitary prolactin
release in both female rats and humans but the decreased
prolactin level alters tumor incidences of reproductive
organs in female rats and not in humans as prolactin is
luteotrophic in rats, but not in primates [35]. Boobis et al.
[9]  termed this lack of conﬁdence as being due to qualita-
tive  species differences.
Therefore,  the objectives of these studies were to (1)
evaluate the Ticagrelor rat two-year carcinogenicity bioas-
say  data, (2) investigate potential mode of action (MOA) for
any  altered tumor ﬁndings and (3) interpret the data using
the  human relevance framework to determine the patient
safety  risk.
2.  Materials and methods
All  procedures were approved by the appropriate insti-
tutional Animal Care and Use Committee (IACUC) in
accordance with The Guide for the Care and Use of Laboratory
Animals. Rats were housed, as outlined within each exper-
iment,  with food and water provided ad libitum, unless
otherwise stated. A standard light–dark cycle was  main-
tained with a timer-regulated light period from 0600 to
1800  h.
2.1.  Carcinogenicity study in rats
The procedures within this study were consistent with
the  guidelines of the EU, US FDA and Japanese MHLW;
prospective FDA protocol concurrence was sought and
received under the Special Protocols procedure [8].
Brieﬂy, seven-week old Wistar rats (Rat/Wistar Han IGS
(Crl:  WI(Glx/BRL/Han)GSBR)) in groups of 50 per sex were
treated  with 0, 20, 60, or 180/120 mg/kg/day Ticagrelor by
oral  gavage in a 2-year carcinogenicity study. High dose
female rats were treated with 180 mg/kg/day and male
rats  with 120 mg/kg/day. In male rats, the 120 mg/kg/day
was selected based on a prior 26-week rat study wherein
increased stomach weight and decreased body weight gain
in  male rats treated with 180 mg/kg/day (data not shown)
was  deemed above a maximum tolerated dose (MTD)
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 and lackFig. 1. Mechanisms of action schematic for carcinogenicity in female rats
in  human).
consistent with unacceptable morbidity/mortality over a
2-year  exposure duration. Additional satellite rats were
treated  with 0 (n = 5/sex), 20, 60 or 180/120 mg/kg/day
Ticagrelor (n = 10/sex/dose) for 52 weeks for toxicoki-
netics (TK) bioanalysis. Ticagrelor was suspended in 1%
carboxymethylcellulose with 0.1% polysorbate 80 (w/v,
vehicle). The dosing volume was 5 mL/kg with the con-
trol  (0 mg/kg/day) group receiving vehicle only. The rats
were  group housed by gender, 5 per home cage. All main
study  animals were examined macroscopically and micro-
scopically with a full tissue list collected. The tissues were
trimmed, embedded in parafﬁn wax and stained with
hematoxylin and eosin (H&E). All slides were examined
microscopically and the ﬁndings peer reviewed.
On Days 1, 3 and during Weeks 26 and 52, 0.3 mL  of
blood was collected from the satellite rats at 4 h post dose
for  0 mg/kg/day rats and at 2, 4, 6, 8, 12 and 24 h post dose
(n  = 3 rats/sex/time point) for TK bioanalysis. The blood was
collected  in 0.5 mL  microtainer tubes containing lithium
heparin (Becton Dickenson, Franklin Lakes, NJ) and TK bio-
analysis  of exposure determined by protein precipitation
and liquid chromatography followed by mass spectromet-
ric  detection (LC-MS/MS).
Rats  were fed rodent chow (Lab Diet, Gray Summit,
MO)  and consumption was measured and recorded weekly
up  to the end of Week 13 for each cage (n = 5 rats).
Between Weeks 14 and 28, food consumption was  mea-
sured  and recorded over approximately one week in every
two  weeks. After Week 28 food consumption was  mea-
sured  and recorded for one week in every four weeks until
the  end of the study.
The  daily mean food consumption was calculated per
rat  per day for each period of recording from the total food
or  water consumption in each cage divided by the number
of  rats in the cage.Body  weights were recorded once pretreatment, daily
for  the ﬁrst 13 weeks of the study and then weekly until end
of  the study. Any rat showing weight loss or deterioration
in condition was weighed more frequently, as necessary. of translation into human (P = progesterone, E = estradiol in rat, estrogen
Statistical analysis of the data were as follows: (1) histo-
logical data using Fishers Exact Test (two-tailed), (2) tumor
data  using SAS (v8.2) PORC MULTITEST at the 5% signif-
icance level, and (3) body weight and food consumption
of the main study rats were analyzed using Hartley’s jack-
knifed  F-max test and Fishers’ F-protected t-test.
2.2. Mechanism of action studies
2.2.1. Genotoxicity
Good Laboratory Practice (GLP) genotoxicity assays
were carried out using standard methods and materials:
Ames in vitro assays, Ames in vitro assay with metabolite
and impurities, mouse lymphoma in vitro assay, and rat
micronucleus in vivo assay [12–15].
2.2.2. Quantitative whole body autoradiography (QWBA)
Male rats or pregnant female rats (Day 18 of gestation)
were treated with 3 mg/kg [3H] Ticagrelor (111.4 MBq/mg).
Rats  were humanely euthanized with carbon dioxide at the
designated  times post-dose. Immediately prior to eutha-
nizing  the rat, a whole blood sample (0.5 mL)  was  collected
into  heparinized tubes by venesection of a tail vein and
aliquots removed for blood radioactivity analysis. Each rat
was  immediately frozen and embedded in a block of methyl
cellulose. Sagittal sections (30 m)  were prepared, freeze-
dried  and applied to phosphor screens along with a series
of  calibration standards containing known concentrations
of radioactivity. After 7 days of exposure, the radioactiv-
ity present in various organs and tissues were determined
using the Cyclone Storage Phosphor system (Packard; Meri-
den,  CT).
Blood sample radioactivity was quantiﬁed in scintilant
for 5 min, together with representative blank and standard
vials  using liquid scintillation analyzer with automatic
quench correction using an external standard method.2.2.3. Pharmacological proﬁling
Ticagrelor and a major active metabolite (AR-C124910)
were evaluated at 10 M in more than 300 receptor,
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nzyme and electrophysiological assays (Ricerca Bio-
ciences LLC) including dopamine D1, D2L and D4.2
eceptors as well as the dopamine transporter using in vitro
adioligand binding assays and methodologies described in
he  literature [16–22]. Human recombinant CHO-K1 cells
ere  used for the dopamine transporter and D4.2 recep-
or, whereas human recombinant CHO cells were used
or  dopamine D1 and D2L receptors. The radiolabeled lig-
nds  were [3H] SCH-23390, [3H] spiperone [3H] dopamine
nd [126]RTI-55 for the D1, D2L and D4.2 receptors and
opamine transporter, respectively. The data were calcu-
ated  as a percentage inhibition of speciﬁc binding at the
est  concentration of 10 M.
Assays with signiﬁcant inhibition (>50% effect) at
0  M were followed up with concentration–response
urves. In the case of the dopamine transporter, a
oncentration–response curve was generated using 10
scending concentrations in half log10 intervals enabling
alculation of the inhibitory concentration ﬁfty percent
IC50), inhibition constant (Ki) and Hill coefﬁcient (NH).
C50 values were determined by a non-linear, least squares
egression analysis using the MathIQTM software (ID Busi-
ess  Solutions Ltd., UK). This software was also used
o  calculate NH. The Ki value was calculated using the
heng–Prusoff equation [23]. These assays were repeated
our  times in order to generate a robust estimate of afﬁnity.
.2.4.  Rat ovariectomized mode of action study
The rat ovariectomized in vivo assay was a modiﬁca-
ion of Brott et al. [24], in that Ticagrelor was (1) dosed
rally once a day for 4 days and (2) on Day 4, Ticagrelor
reatment was considered as t = 0 h and the rats dosed with
stradiol  (2 g/rat) at t = 1 h with blood collected at various
ime  points for prolactin analysis.
Female Han Wistar rats (350–375 g; n = 20) were
variectomized and cannulated at Harlan (Indianapolis,
N). Brieﬂy, rats were anesthetized, ovariectomized and
llowed  to recover for three to ﬁve days. The rats were
hen re-anesthetized, catheters placed in both jugular and
emoral  veins and externalized at the nape of the neck, and
llowed  to recover for 7–14 days prior to study initiation.
he jugular vein catheter was used for intravenous estra-
iol  administration, whereas the femoral vein catheter was
sed  for remote blood sampling for prolactin analysis. The
ay  prior to experiment initiation, rats were jacketed, teth-
red  and housed individually in home cages at 23 ± 1 ◦C.
Ticagrelor (180 mg/kg/day; n = 20) or vehicle (1% (w/v)
odium carboxymethylcellulose in 0.1% (w/v) polysorbate
0;  n = 10), were administered orally (n = 10 rats/group).
ive hours after Ticagrelor treatment on Day 1, 0.5 mL  blood
as  collected into lithium heparin tubes for TK bioanalysis
f  exposure determined by protein precipitation and liquid
hromatography followed by mass spectrometric detection
LC-MS/MS). On Day 4, rats were treated with Ticagrelor or
ehicle  1 h before estradiol (E2; 2 g/rat). Blood (0.3 mL)
as  collected from the femoral vein at the following time
oints:  pre-Ticagrelor dose and 0.75, 1, 1.5, 2, 2.5, 3, 3.5,
,  4.5 and 5 h post-Ticagrelor dose. The 1 h blood collec-
ion  was just prior to E2 treatment. Blood was transferred
nto microcentrifuge tubes containing the anti-coagulant
ithium heparin, and plasma isolated by centrifugationrts 1 (2014) 1202–1212 1205
and then frozen at −80 ◦C until analyzed. Rats were not
handled for blood collection; all samples were collected
remotely via the implanted catheters (e.g. from outside
of  the home cage). Plasma prolactin levels were evalu-
ated by ELISA, according to the Manufacturer’s instructions
(Kamaya Biomedical Company, Seattle WA;  catalog KT-
203),  except a lower standard was  inserted into the assay
bringing the lower limits of quantiﬁcation (LLOQ) down
to  1.3 ng/mL. This 1.3 ng/mL LLOQ was  deemed accept-
able because it was above the mean plus two  times the
standard deviation of 20 assay diluent samples. The intra-
and  inter-assay variability were <10%. Several measure-
ments of prolactin were at or below the LLOQ, which was
reported as the LLOQ value. Area under the curve (AUC)
value for prolactin was calculated for each rat using the
Trapezoidal Rule, with data starting from 1 h after Tica-
grelor dose, which was  just before estradiol dosing, to 5 h
post-Ticagrelor dose, collected at 30 min  intervals. For the
purpose  of AUC calculation, the 1 h time point was treated
as  time point zero. The LLOQ was treated as the baseline (or
zero  prolactin) value and was  subtracted from all prolactin
values prior to AUC calculation, to express AUC values rela-
tive  to the baseline. The mean values were log transformed
to stabilize the variance prior to analysis. A t-test was then
performed on these log-transformed AUC values. Statistical
analysis was  not performed on the data at each individual
time point.
3.  Results
3.1. Rat carcinogenicity bioassay
The two year rat carcinogenicity bioassay evaluated
Ticagrelor at 0, 20, 60 and 180/120 mg/kg/day with
female high dose being 180 and male high dose being
120 mg/kg/day. The AUC exposure of Ticagrelor in high
dose  female rats (Table 1) remained relatively consistent
between Day 1, Week 26 and Week 52, whereas exposure
of  the metabolite increased between Day 1 and Week 26
and  then was  similar between Week 26 and Week 52. At
60  mg/kg/day male rats had lower Ticagrelor exposure and
higher  metabolite exposure, compared to female rats.
Microscopic examination of the tissues revealed that
the  high dose treated female rats (180 mg/kg/day) had
a  statistically signiﬁcantly increased incidence of uterine
adenocarcinomas (p < 0.001), while there were statistically
signiﬁcantly decreased incidences of tumors/hyperplasia
in the pituitary (p < 0.05), and mammary (p < 0.05) glands
(Table  2).
The  treatment related effect in the high dose rats
(180 mg/kg/day) on the incidence of mammary tumors
(decreased) and uterine tumors (increased) are shown in
Fig.  2. The coincidence between mammary and uterine
tumors showed an inverse relationship in that the rats with
a  uterine tumor did not have mammary tumors and the rats
with  mammary tumors did not have a uterine tumor.
Male and female rats in the control and Ticagrelor
groups gained body weight throughout the study but the
male  Ticagrelor-treated rats gained less body weight than
the  controls over the study period in a dose trend, with the
high  dose group weighing within 10% of the control group
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Fig. 2. Uterine and mammary tumor incidences and co-incidences in rat 2 year carcinogenicity study. Rats were dosed daily per gavage for 2 years,
necropsied,  and tissues collected, trimmed, embedded in parafﬁn wax, stained with hematoxylin and eosin and microscopically examined with peer
review.  The number of rats per group were 99, 50, 49 and 50 for 0, 20, 60 and 180 mg/kg/day Ticagrelor.
Fig. 3. Body weight and food consumption in rat 2 year carcinogenicity study (female rat). Rats were dosed daily per gavage for 2 years with (A) body
weights  taken daily from pretrial through Week 13 and then weekly until end of study and (B) food consumption recorded weekly through Week 13, every
other  week between Weeks 14 and 28 and once every four weeks from Week 29 to end of study. The numbers of rats per group were 99, and 50 for 0 and
180  mg/kg/day Ticagrelor. *p < 0.05, **p < 0.01, ***p < 0.001.
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Table 1
Plasma exposure in 2 year rat carcinogenicity study (n = 5 rats/group).
Sex Analyte Treatment AZD6140 (mg/kg/day) AUC (h mol/L; mean)
Day 1 Week 26 Week 52
Female Ticagrelor 20 21.1 23.2 31.3
Female Ticagrelor 60 191 131 163
Female Ticagrelor 180 545 589 595
Female Metabolite 20 5.4 7.2 9.3
Female Metabolite 60 30.8 30.5 39.4
Female Metabolite 180 66.4 195 195
Male Ticagrelor 20 11.9 16.8 24.7
Male Ticagrelor 60 85.5 98.8 129
Male Ticagrelor 120 200 222 311
Male Metabolite 20 6.9 16.3 20.0
Male Metabolite 60 45.8 77.6 102.0
Male Metabolite 120 93.1 211 257
Table 2
Endocrine-related tumor ﬁndings (percentage) in rat 2-year carcinogenicity bioassay (n = 100, 50, 49 and 50 female rats for control, 20, 60 and 180 mg/kg/day
Ticagrelor).
0 mg/kg/day 20 mg/kg/day 60 mg/kg/day 180 mg/kg/day
Uterine adenocarcinoma 10 10 12 42***
Uterine adenosquamous carcinoma 0  0 2 4
Uterine squamous cell carcinoma 0 0 0 2
Mammary ﬁbroadenoma 14 22 16 2*
Pituitary hyperplasia and adenoma 66 64 73 50*
*
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gPituitary anterior lobe adenoma in decedent rats 64 
* p < 0.05.
*** p < 0.001.
t the end of the study. The body weights of the Ticagrelor
ow and mid  dose treated female rats were similar to the
ontrol  group (data not shown), but the body weights of
he  high dose treated (180 mg/kg/day) female rats were sig-
iﬁcantly  less (p < 0.001) than the control rats, starting at
pproximately Week 50 through to the end of study and
ere  approximately 20% lower than the control group by
he  end of study (Fig. 3A).
There were no consistent food consumption differences
ith Ticagrelor treatment in male rats but in female rats
reated  with high dose Ticagrelor (180 mg/kg/day) there
as  increased food consumption early during the study and
hen  signiﬁcantly decreased food consumption in 10 out
f  the last 14 measurements (Fig. 3B; p < 0.05), such that
he  decreased food intake starting at Week 52 (food intake
easured every 4 weeks after Week 28) corresponded with
he  decreased body weight gain starting at Week 50.
.2.  Mode of action studies
.2.1.  Genotoxicity
The  Ames, mouse lymphoma and micronucleus assays
or  Ticagrelor, and Ames and mouse lymphoma assays for
ajor  metabolites were negative (Table 3). Further, no
egulatory authority has commented that Ticagrelor rep-
esents  a genotoxicity risk [25].
.2.2. QWBA
Although there were differences in timings of maximal
xposures, high levels of radioactivity were observed in
drenal,  heart, kidney, liver, pancreas, pituitary, salivary
land, stomach wall and the thyroid (Table 4). Intermediate55 53 35
levels were observed in the skeletal muscles, spleen, thy-
mus  and placenta, whereas minimal levels (<0.25 fold of
blood  levels) were in brain, spinal cord and fetus. Thus,
Ticagrelor was  deemed effectively excluded from the brain
and  spinal tissues by the blood brain barrier.
3.2.3. Pharmacological proﬁle
Ticagrelor and its metabolite (main circulating metabo-
lite  of Ticagrelor and active at the P2Y12 receptor) were
evaluated for activity at more than 300 secondary targets
using  in vitro radioligand binding, enzyme, and electro-
physiological assays. When tested at a single concentration
of 10 M,  neither Ticagrelor nor metabolite caused inhibi-
tion  of radioligand binding at the D1, D2L and D4.2 receptors.
Ticagrelor displaced [125I] Iometopane (RTI-55)
from the human dopamine transporter recombinantly
expressed in Chinese hamster ovary (CHO) cells, with a pKi
value of 6.79 ± 0.05 (0.202 M,  mean ± standard deviation,
n  = 4 separate experiments; Fig. 4A). The rat free systemic
exposure maximal concentration (Cmax) in the high dose
group of 0.502 M (based on 99.0% protein binding) was
above  the Ticagrelor IC50 of DAT, but rat free systemic
exposure in the mid  and low dose group Cmax values of
0.157 and 0.043 M were below the Ticagrelor IC50 of
DAT. The human free systemic Cmax in clinical studies of
0.012  M (based on 99.2% protein binding) was more than
one  log below the Ticagrelor IC50 of DAT.
The metabolite inhibited radioligand binding at the
dopamine transporter with a pKi value of 6.12 ± 0.08
(0.8  M,  mean ± standard deviation, n = 4; Fig. 4B). The rat
and  human free systemic Cmax values were more than one
log  below the metabolite IC50 of DAT.
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Table 3
Non-clinical genotoxicity study results and conclusion.
Study type Sex/strain Dose concentration Dose,
mg/kg
Results  Cmax, g/mL AUC, g h/mL Conclusion Reference
Ames in vitro
assay
TA1535
TA100
TA102
TA98
TA1537
3–3000  g/plate Na No increased
frequency of
reverse
mutations with
or  without
metabolic
activation
Na Na Negative [47]
Mouse
lymphoma
in  vitro
L5178Y/TK  + 1
mouse
lymphoma
cells
15.7–41.8  g/mL
(4 h + S9)
5.23–15.7 g/mL
(4 h − S9)
15.7–36.6 t/mL
(24 h − S9)
Na  No increased
number of
clones
associated with
treatment
Na  Na Negative [48]
Rat
micronucleus
In  vivo
Alderly  Park
(Wistar
derived)
M&F
Na  2000 No increased
frequency of
micronuclei at
24  or 48 h
post-dose
19 = 24 (M)
45–53 (F)
794–1240  (M)
1140–1360 (F)
Negative [49,50]
Na – Not applicable.
Table 4
Quantitative whole body autoradiography.
5 min  0.5 h 2 h 4 h
Male
Adrenal gland 11.35/5.33a 5.26/5.16 1.19/2.57 0.81/2.24
Brain 0.05/0.02 0.04/0.04 0.02/0.04 0.02/0.06
Brown fat 1.35/0.63 0.95/0.93 0.46/0.99 0.52/1.44
Eye 0.50/0.23 0.04/0.04 0.01/0.02 0.14/0.39
Heart 9.15/4.29 4.94/4.84 1.73/3.74 1.18 3.27
Kidney 10.62/4.98 6.77/6.64 2.22/4.79 1.74/4.87
Liver 16.11/7.56 8.44/8.27 3.20/6.97 2.42/6.70
Lung 7.31/3.43 3.90/3.82 2.09/4.51 1.55/4.29
Pancreas 7.35/3.45 7.83/7.68 2.78/6.00 2.08/5.76
Pituitary gland 8.03/3.77 7.03/6.89 1.84/3.97 1.65/4.57
Salivary gland 3.66/1.72 5.57/5.46 2.14/4.62 1.59/4.40
Skeletal muscle 3.15/1.48 3.26/3.20 1.48/3.20 1.16/3.21
Spinal cord 0.05/0.02 0.04/0.04 0.02/0.04 0.02/0.06
Spleen 4.86/2.28 3.81/3.74 1.51/3.29 0.82/2.27
Stomach wall 7.11/3.34 7.17/7.03 2.31/4.99 1.32/3.66
Thymus 0.99/0.46 1.28/1.25 1.37/2.96 1.33/3.68
Thyroid gland 7.84/3.68 3.85/3.77 2.60/5.62 1.19/3.30
Blood (LSC) 2.131 1.02 0.463 0.361
Female
Fetus 0.03/0.01 0.06/0.07 0.07/0.25 0.03/0.13
Placenta 6.42/2.59 2.86/3.31 1.02/3.62 0.39/1.63
Fig. 4. Inhibition of dopamine transporter (DAT) by (A) Ticagrelor and (B)
metabolite. Ticagrelor had substantial inhibition of the dopamine trans-
porter in rats (>50%) and minimal inhibition in humans at free systemic
grelor in the rat two-year carcinogenicity bioassay, (2)Blood (LSC) 2.474 0.864 0.282 0.24
a Raw values of g equivalent/g/fold of blood value.
3.2.4. Investigational rat ovariectomized study
Ticagrelor treated ovariectomized rats were treated for
four  days with Ticagrelor and then stimulated with estra-
diol  on Day 4 of treatment. Exposure of Ticagrelor and
metabolite on Day 1 of dosing were similar to Day 1 and
Week  26 exposure in the carcinogenicity bioassay (Table 5).
Vehicle  control treated rats with estradiol-stimulation
had increased prolactin plasma levels between 3 and
4.5  h post vehicle treatment and an AUC of 25.24 ± 18.62
(mean ± standard deviation) (Fig. 5). At 180 mg/kg/day
the peripherally-restricted Ticagrelor all but completely
blocked the estradiol-induced prolactin release, with an
AUC  of 9.7 ± 5.53, which was signiﬁcantly different from
the  control group (p < 0.01). Based upon these ﬁndings,Cmax levels. The metabolite had no inhibition of the dopamine transporter
in rats or humans at the observed free systemic Cmax levels observed in
the corresponding specie.
Ticagrelor was deemed an inhibitor of estrogen-stimulated
prolactin release in the female rat, at the dosage tested.
4.  Discussion
The objective of these studies were to (1) evaluate Tica-investigate potential MOA  for any test-article treatment
associated tumor ﬁndings and (3) interpret the carcinoge-
nicity bioassay and MoA  study ﬁndings using the human
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Table 5
Plasma exposure (5 h post dose) in the ovariectomized rat study compared to carcinogenicity bioassay (n = 10 and 5/group, respectively).
Analyte Treatment (mg/kg/day) Exposure (M; mean ± SD)
Ovariectomized study Carcinogenicity Bioassay
Day  1 Day 1 Week 26
Ticagrelor 180 33.2 ± 10.
Metabolite  180 8.1 ± 2.7 
Fig. 5. Ticagrelor inhibits estradiol-induced prolactin release. Dual cannu-
lated and ovariectomized rats were dosed 4 days with 0 or 180 mg/kg/day
Ticagrelor. On Day 4, Ticagrelor was t = 0 h. Estradiol (2 g/rat) was  dosed
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elevance framework to determine the patient safety risk
f  Ticagrelor, a P2Y12 receptor antagonist.
In  summary, in the rat carcinogenicity bioassay, Tica-
relor increased the incidence of uterine tumors and
ecreased the incidence of mammary and pituitary tumors
n  the high dose female group; there were no other
reatment-associated tumors in any of the treatment
roups. The ﬁrst concept of the human relevance frame-
ork  is to determine if the weight of evidence is sufﬁcient
o  establish a MOA  in animals. The ﬁndings could be
ue  to Ticagrelor being carcinogenic or due to some epi-
enetic MOA. It was anticipated that Ticagrelor P2Y12
eceptor antagonism, would not be linked with tar-
et  related carcinogenicity because marketed irreversible
2Y12 antagonists such as Clopidogrel or Prasugrel, did not
lter  tumor incidences in their respective 2 year carcino-
enicity bioassays [4,5]. Therefore, a non-P2Y12 mediated
ode of action needed to be identiﬁed in order to under-
tand the potential translational relevance of the tumor
ncidences found in female rats. Ticagrelor was also not
ssociated with chemical/structural related carcinogeni-
ity as the genotoxicity studies were uniformly negative for
icagrelor  and major metabolite, and afﬁrmed by all regula-
ory  authorities to date; thus the MoA  for treatment-related
umors in female rats is not related to P2Y12 receptor antag-
nism  or DNA alterations, but must be the result of an
pigenetic mechanism.
The  rat carcinogenicity study ﬁndings including inverse
elationships between incidence of uterine, with mam-
ary  and anterior pituitary tumors, and body weight gainffects  were consistent with those previously reported
or centrally-acting dopaminergic agonists (i.e. Bromocrip-
ine) [26] and so the epigenetic MOA  hypothesis was
hat  Ticagrelor was carcinogenic in female rats due to6 35.9 ± 17.9 37.9 ± 10.5
3.9 ± 1.4 10.0 ± 4.4
altered  prolactin drive, possibly via the dopaminergic
system. Evidence in the current studies supporting this
hypothesis included (1) primary and secondary pharmaco-
logical testing identifying Ticagrelor binding and inhibiting
the  dopamine transporter, and (2) Ticagrelor inhibition
of estrogen-stimulated prolactin release was  conﬁrmed
in  the ovariectomized estradiol-challenge model, at the
dose  associated with treatment-related tumor changes in
the  carcinogenicity bioassay. A difference from centrally-
acting dopaminergic agonists was that Ticagrelor was
peripherally restricted and would increase dopamine lev-
els  in only the pituitary by inhibiting dopamine reuptake
(Fig. 1). In the pituitary this effect is possible because of the
lack  of blood brain barrier in this organ.
In addition to similarities in altered tumor incidences,
both centrally-acting dopaminergic agonists and Ticagrelor
altered body weight gain. In fact, tumor incidences and
body  weight gain are closely inter-connected based on
dopamine inhibition of prolactin secretion. Prolactin is
orexigenic (an appetite stimulant) and induces hyper-
phagia [27]. The dopamine agonist bromocriptine, which
inhibits prolactin release, also inhibited weight gain in
Wistar  rats [28]. Prolactin is a peptide hormone pro-
duced and secreted by lactotrophs in the anterior lobe of
the  pituitary gland; in the female rat; prolactin is under
positive regulation by estradiol and negative regulation
by dopamine [29–32]. Estradiol stimulates the synthesis
and release of prolactin and can act directly or indi-
rectly to modulate the activity of the dopaminergic system
on  prolactin release from the pituitary [33]. Dopamine
from hypothalamic dopaminergic neurons decreases pro-
lactin  release by exerting an inhibiting effect on the
lactotrophs via the dopamine (D2) receptor [31]. Dopa-
minergic compounds known to inhibit estradiol-induced
prolactin release [24] such as the centrally-acting D2 ago-
nist  bromocriptine are known to alter tumor incidences in
female  rats with a proﬁle similar to Ticagrelor [26,34]. More
speciﬁcally, bromocriptine can induce hypoprolactinemia
in rats and humans, but increases uterine and decreases
mammary tumors only in rats, which is postulated to be
due  to a direct prolactin impact on rat ovarian steroidogen-
esis in aged rats [34,35]. A difference between Ticagrelor
and centrally-acting dopamine agonists is that the QWBA
data  show that Ticagrelor is peripherally restricted and
thus  not likely to inﬂuence dopaminergic mechanisms in
the  hypothalamic end of the hypothalamic–hypophyseal
axis. However, the QWBA study did demonstrate Ticagrelor
levels in the pituitary gland, with the anterior pituitary
being outside of the blood brain barrier. Other peripherally-
restricted compounds such as the dopamine receptor
agonist carmoxirole impacting dopaminergic regulation of
prolactin  release would be active at this hypophyseal end
gy Repo1210 D.A. Brott et al. / Toxicolo
of the axis [24]. Therefore, it is reasonable to hypothesize
that Ticagrelor exerts its effect at the level of the anterior
pituitary gland, outside the blood brain barrier and due to
peripheral  exposure. Alternatively, because the effect only
occurs  with the highest systemic exposure to Ticagrelor
tested in rats we cannot categorically rule out the possi-
bility  that the effect is in part attributable to a very small
fraction of the Ticagrelor exposure that may  penetrate the
rat  blood brain barrier.
Another  difference between Ticagrelor and the
dopamine agonists evaluated to date is that Ticagrelor’s
MoA  is inhibition of the dopamine transporter (DAT)
and lacks intrinsic dopamine agonist activity. To our
knowledge, Ticagrelor is the ﬁrst peripherally-restricted
compound with non-target related DAT activity above the
IC50 value to undergo a 2-year carcinogenicity bioassay.
DAT inhibition will increase endogenous dopamine levels
by  blocking dopamine reuptake and thereby have similar
downstream effects as treatment with dopamine or
dopamine agonists.
Ticagrelor free systemic exposures in the carcinogene-
sis study and the DAT IC50 give credence as to why altered
tumor incidences were only observed in the high dose rats,
since  the Cmax of the high dose females was above the Tica-
grelor IC50 of DAT while the Cmax in the mid  and low dose
groups were below the Ticagrelor IC50 of DAT.
In the context of the human relevance framework [9],
the  similarity of multi-organ carcinogenicity data and body
weight  gain proﬁles between Ticagrelor and other dopa-
minergic compounds is sufﬁcient weight of evidence to
establish  inhibition of dopamine reuptake and potentiat-
ion  of endogenous dopamine agonist activity at the level
of  the anterior pituitary by Ticagrelor as its MOA  for the
ﬁndings in the rat carcinogenicity bioassay. In addition,
since Ticagrelor is peripherally restricted it is likely that
this  inhibition of dopamine transport and potentiation of
endogenous dopamine occurs at the level of the lactotrophs
in  the pituitary, thus peripheral and not central dopamine
levels are most likely responsible for the rat carcinogenesis
ﬁndings.
The human relevance framework helps classify the
human patient safety risk from high conﬁdence in the
rodent carcinogenicity data translating into patient safety
risk,  to the mechanism of action studies determining the rat
carcinogenicity data has a MOA  not plausible in human and
thereby  no patient safety risk. Three characterized exam-
ples  of the application of the human relevance framework
are:
(1) high conﬁdence in the human relevance of the ethylene
oxide rat carcinogenicity data because it was found to
be genotoxic in in vitro and in vivo studies, a mechanism
which is not speciﬁc to a single species [11],
(2)  low conﬁdence in the human relevance of
thiamethoxam-related mouse liver tumors because,
although the MOA  is found in both rodents and
humans, the key metabolites associated with the
tumors generated in the mouse were not found in
sufﬁcient concentration in rat or human [36]. This
low conﬁdence in translation is also referred to asrts 1 (2014) 1202–1212
quantitative differences in key events between animals
and humans [9] and
(3) Lack of conﬁdence in human relevance of centrally
active (peripheral and brain exposure) dopamine ago-
nist induced uterine tumors and decreased mammary
tumors,  because the mode of action is nongenotoxic and
female rat speciﬁc [34,37]. This lack of conﬁdence in
translation is also referred to as qualitative differences
between animals and humans [9].
Based  on the human relevance framework, the next
step in evaluating patient safety risk was to determine if
the  Ticagrelor rat carcinogenicity MOA  was  plausible in
humans.  In order to determine this, there was a need to
understand both the differences between DAT inhibition
in  the rat versus human as well as how hypoprolactinemia
can lead to uterine tumors and if the mechanism is similar
in  humans.
In normal reproductive cycling rats, the estrus cycle
consists of 4 days (proestrus, estrus, diestrus-1 and
diestrus-2). Prolactin levels are low throughout the estrus
cycle  except during the afternoon of proestrus, which is
driven  by the rising estrogen levels in the morning of
proestrus [38]. The prolactin released during proestrus is
luteotropic in that it promotes rescue of the corpus luteum
from  degradation, but prolactin is also essential for pro-
gesterone production after ovulation, which antagonizes
the estradiol-stimulated uterine growth [39]. With aging
in  rats, there is a progressive loss of hypothalamic dopa-
minergic neurons, which decreases the level of dopamine
in  the pituitary and resulting in higher prolactin release
[40,41]. The increased prolactin levels are a critical fac-
tor  in the age related transformation from normal estrus
cycling into pseudopregnancy and ultimately leading to
anestrus  (reproductive senescence) with the rat in a state of
progesterone dominance. Therefore, in the rat, age-related
anestrus can be a result of decreased dopamine levels. In
untreated control rats there is also a negative relationship
between the presence of uterine and mammary tumors
[42]. The same relationship was  observed in the current
study. In rats, prolactin is the major stimulating factor for
the  development of mammary tumors which is closely
related to the presence of pituitary hyperplasia or tumor.
Animals with a uterine tumor have signiﬁcantly lower inci-
dence  of mammary tumors and vice versa, demonstrating
the close biological link between these tumor patterns
and incidence [42]. Increasing dopamine levels in aging
rats  will decrease prolactin levels, which cause not only
decreased stimulation mammary glands, but also luteol-
ysis,  new follicle development and thereby the rat will
continue to be exposed to recurrent estradiol. Thus in older
female  rats, decreased prolactin levels will increase the
estradiol:progesterone ratio over a series of cycles (relative
estrogen dominance). This prolonged estrogen stimulation
of  the endometrium can lead to the observed endometrial
adenocarcinoma seen with bromocriptine or other com-
pounds  that increase dopaminergic stimulation.Unlike the rat, prolactin is not essential for adequate
progesterone production by the corpus luteum in human
[43].  The differences in the role of prolactin between rat
and  human in female reproductive cyclicity are the reasons
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hy the tumorigenic effects on the uterus of compounds
hat increase dopamine levels are considered to be rat spe-
iﬁc  and not relevant to pathophysiological conditions in
uman,  based on qualitative species differences between
at  and human.
Epidemiological studies support the rat speciﬁc tumori-
enic potential of compounds like bromocriptine in that
ompounds that increased dopamine levels are not asso-
iated  with increased endometrial adenocarcinomas in
omen  [26,34,44,45].
A  potential limitation of these studies includes the
ack of hormone (i.e. prolactin, progesterone and estradiol)
easurements in rats. Hormone levels were not included
n  the 2-year rat carcinogenicity study since based on other
2Y12 antagonists the altered tumor incidences were unex-
ected  ﬁndings. An additional study to evaluate Ticagrelor
nduced hormone changes would have been very difﬁcult
or  the following reasons. Based on the ﬁndings that food-
ntake  and weight gain were not decreased until after 52
eeks  of dosing within the carcinogenicity study, thus a
tudy  would either have required the use of older female
ats  (greater than a year of age) or a chronic study of dosing
ats  for more than a year. As progressive aging of the neu-
oendocrine system show great inter-individual variation,
arge  group sizes would have been require. Furthermore,
ormonal monitoring in cycling females requires staging
nd  multiple sampling, and since prolactin is a stress sen-
itive  hormone this would restrict sampling by indwelling
atheters [46]. Therefore, we thought such large, com-
licated long term studies unnecessary to establish MOA
ithin  the rat, based on the unique ﬁndings of altered
umor incidences being similar between Ticagrelor and
opaminergic compounds and the supportive ﬁnding of the
OA  studies.
A  second potential limitation of our data includes the
ack  of hormone (i.e. prolactin, progesterone and estrogen)
easurements in clinical studies. Based on the qualitative
pecies differences of Ticagrelor and other dopaminergic
ompounds being post prolactin secretion (Fig. 1), hormone
nalysis would have been expected to be very important in
linical  studies with expected ﬁndings being altered pro-
actin  levels without changes in progesterone or estrogen
evels. However, based on quantitative species differences,
ormone measurement was deemed not appropriate in
linical  studies, based on (1) Ticagrelor free systemic expo-
ure  in the rat was above the Ticagrelor IC50 of DAT that
ould result in increased prolactin in the rat, but (2) Tica-
relor  free systemic exposure in humans was below the
icagrelor IC50 of DAT and so prolactin increase due to DAT
nhibition would not be expected to be observed in the clin-
cal  setting and thus the rationale as to why hormone levels
ere  not evaluated in clinical studies. Therefore qualitative
pecies differences explain why the rat tumor ﬁndings pose
o  human safety risk, while quantitative species differ-
nces explain the rat tumor ﬁndings (DAT inhibition above
C50 value in high dose treated rats and below IC50 in mid
nd  low dose rats) and why hormone analysis in clinical
tudies was not appropriate.
In  summary, Ticagrelor an orally available, direct act-
ng,  competitive and reversible P2Y12 receptor antagonist
ncreased uterine tumors and decreased mammary and
[rts 1 (2014) 1202–1212 1211
pituitary  tumors in the rat 2-year carcinogenicity bioas-
say.  Mode of action studies showed that the mechanism
as epigenetic interruption of dopamine regulation of
prolactin release from the anterior pituitary gland. The
investigational study determined peripherally-restricted
compounds that increase dopamine levels can alter tumor
incidences with a MoA  consistent with those observed for
centrally  active dopamine agonists, suggesting centrally
active dopaminergic compounds could be altering tumor
incidences at least partially due to peripheral exposure.
This MoA  of decreased prolactin release is luteotrophic
in rats that with advancing age lead to disturbances in
female  reproductive organs and increased uterine tumors.
Prolactin is not luteotrophic in humans and therefore
the rat carcinogenicity data for Ticagrelor do not pose a
patient  safety risk, based on qualitative species differences
between rat and human.
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